Maxim Group restated their hold rating on shares of PainReform (NASDAQ:PRFX – Free Report) in a research report report published on Thursday morning, Marketbeat reports.
PainReform Trading Down 8.9 %
PRFX opened at $0.64 on Thursday. PainReform has a 12-month low of $0.53 and a 12-month high of $20.16. The firm has a 50 day moving average of $0.59 and a two-hundred day moving average of $0.61. The firm has a market capitalization of $1.29 million, a PE ratio of -0.02 and a beta of 0.54.
PainReform (NASDAQ:PRFX – Get Free Report) last issued its earnings results on Thursday, August 15th. The company reported ($0.40) earnings per share (EPS) for the quarter.
Institutional Trading of PainReform
About PainReform
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.
Featured Articles
- Five stocks we like better than PainReform
- How to Invest in the FAANG Stocks
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is the Euro STOXX 50 Index?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for PainReform Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PainReform and related companies with MarketBeat.com's FREE daily email newsletter.